Key points are not available for this paper at this time.
Our liquid biopsy approach provides a molecularly based tool for tumor characterization, and is the first to indicate clinical utility of ctDNA for longitudinal surveillance of DMGs.
Panditharatna et al. (Mon,) studied this question.